What is Zacks Small Cap’s Estimate for RVPH Q2 Earnings?

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) – Stock analysts at Zacks Small Cap issued their Q2 2025 earnings per share estimates for shares of Reviva Pharmaceuticals in a research report issued on Thursday, May 22nd. Zacks Small Cap analyst J. Vandermosten forecasts that the company will earn ($0.13) per share for the quarter. The consensus estimate for Reviva Pharmaceuticals’ current full-year earnings is ($0.97) per share. Zacks Small Cap also issued estimates for Reviva Pharmaceuticals’ Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at ($0.14) EPS and FY2027 earnings at ($0.16) EPS.

Separately, D. Boral Capital cut their price objective on Reviva Pharmaceuticals from $8.00 to $3.00 and set a “buy” rating for the company in a research report on Tuesday, May 20th. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $9.00.

Reviva Pharmaceuticals Stock Performance

Shares of NASDAQ:RVPH opened at $1.03 on Monday. Reviva Pharmaceuticals has a one year low of $0.49 and a one year high of $4.28. The stock has a fifty day moving average of $0.83 and a 200-day moving average of $1.34. The company has a market capitalization of $48.14 million, a PE ratio of -0.93 and a beta of 0.08.

Reviva Pharmaceuticals (NASDAQ:RVPH) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.08.

Institutional Trading of Reviva Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Raymond James Financial Inc. purchased a new stake in shares of Reviva Pharmaceuticals in the fourth quarter valued at $25,000. Cornerstone Select Advisors LLC purchased a new stake in shares of Reviva Pharmaceuticals during the fourth quarter worth $32,000. Drive Wealth Management LLC purchased a new stake in shares of Reviva Pharmaceuticals during the fourth quarter worth $36,000. BluePointe Capital Management LLC raised its holdings in shares of Reviva Pharmaceuticals by 354.7% during the first quarter. BluePointe Capital Management LLC now owns 47,185 shares of the company’s stock worth $45,000 after acquiring an additional 36,807 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of Reviva Pharmaceuticals during the fourth quarter worth $45,000. Hedge funds and other institutional investors own 63.18% of the company’s stock.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.